The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR).
BCL2
multiple myeloma
t(11;14)
venetoclax
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
23
05
2023
revised:
05
06
2023
accepted:
13
06
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
The prognostic impact of t(11;14) in multiple myeloma (MM) needs to be better understood to inform future treatment decisions. The Australian Lymphoma Leukaemia Group embarked on a retrospective, observational cohort study using real-world data to interrogate treatment patterns and outcomes in 74 MM patients with t(11;14) [t(11;14)-MM] diagnosed over 10 years. This was compared to 159 and 111 MM patients with high-risk IgH translocations (IgH HR-MM) and hyperdiploidy (Hyperdiploid-MM), respectively, from the Australian Myeloma and Related Diseases Registry. No appreciable differences in age, gender, ISS, LDH levels, 1q21 or del(17p) status, or treatment patterns were observed between groups. Median PFS-1 was not different between groups but both t(11;14)-MM and IgH HR-MM had an inferior PFS-2 vs. Hyperdiploid-MM: median PFS-2 8.2 months, 10.0 months, and 19.8 months (
Identifiants
pubmed: 37601874
doi: 10.1002/jha2.742
pii: JHA2742
pmc: PMC10435683
doi:
Types de publication
Journal Article
Langues
eng
Pagination
639-646Informations de copyright
© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The MRDR has received funding from Abbvie, Amgen, Antengene, Bristol‐Myers Squibb, Celgene, Gilead, GSK, Janssen, Novartis, Sanofi, and Takeda.
Références
Front Immunol. 2019 May 21;10:1121
pubmed: 31231360
Genes Chromosomes Cancer. 2016 Sep;55(9):710-8
pubmed: 27152944
Blood. 2017 Nov 30;130(22):2401-2409
pubmed: 29018077
NPJ Precis Oncol. 2022 Oct 19;6(1):73
pubmed: 36261486
Immunol Lett. 2013 Sep-Oct;155(1-2):36-9
pubmed: 24095849
J Clin Oncol. 2021 Nov 10;39(32):3602-3612
pubmed: 34388020
Blood Cancer J. 2022 Mar 23;12(3):46
pubmed: 35322025
Leukemia. 2014 Jan;28(1):210-2
pubmed: 23860449
Front Oncol. 2020 Oct 26;10:538126
pubmed: 33194599
Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):149-157
pubmed: 34588149
Best Pract Res Clin Haematol. 2007 Dec;20(4):571-96
pubmed: 18070707
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
Biol Blood Marrow Transplant. 2013 Aug;19(8):1227-32
pubmed: 23733001
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Br J Haematol. 2021 Oct;195(1):e113-e116
pubmed: 34165783
J Pers Med. 2021 May 24;11(6):
pubmed: 34073976
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Am J Cancer Res. 2022 Jul 15;12(7):2950-2965
pubmed: 35968339
Mayo Clin Proc. 2013 Apr;88(4):360-76
pubmed: 23541011
Blood Rev. 2020 May;41:100643
pubmed: 31818702
BMC Med Res Methodol. 2016 Nov 9;16(1):151
pubmed: 27829380
Blood Adv. 2021 Oct 12;5(19):3748-3759
pubmed: 34470049
Am J Hematol. 2021 Apr 1;96(4):418-427
pubmed: 33368455
Eur J Haematol. 2019 Dec;103(6):588-596
pubmed: 31487754
Leukemia. 2018 Jan;32(1):131-138
pubmed: 28655925
Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e510-e520
pubmed: 33785297
Blood. 2013 Apr 25;121(17):3413-9
pubmed: 23435460
Lancet Oncol. 2020 Dec;21(12):1630-1642
pubmed: 33129376
Am J Hematol. 2020 May;95(5):548-567
pubmed: 32212178